Results 151 to 160 of about 29,046 (192)

Fondaparinux: an overview

Expert Review of Cardiovascular Therapy, 2009
Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring.
Sunil K, Nadar, Deepak, Goyal, Eduard, Shantsila, Pritwish, Banerjee, Gregory Y H, Lip   +4 more
openaire   +2 more sources

Fondaparinux-sodium

Reactions Weekly, 2022
  +5 more sources

Fondaparinux

Journal of the American Academy of Orthopaedic Surgeons, 2004
Alexander G G, Turpie, Bengt I, Eriksson, Kenneth A, Bauer, Michael R, Lassen   +3 more
openaire   +2 more sources

Fondaparinux sodium

Reactions Weekly, 2021
  +4 more sources

Fondaparinux

2021
openaire   +1 more source

Fondaparinux

2022
openaire   +1 more source

Fondaparinux sodium

Reactions Weekly, 2010
openaire   +2 more sources

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial

Lancet, The, 2002
Bengt I Eriksson
exaly  

Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes

New England Journal of Medicine, 2006
Salim Yusuf, Rizwan Afzal, Janice Pogue
exaly  

Fondaparinux

2008
Singh Sindhu, Peter Silberstein
openaire   +1 more source